- Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2-advanced breast cancer (DAWNA-2): A phase III trialXu, B.; Zhang, Q. Y.; Zhang, P.; Tong, Z.; Sun, T.; Li, W.; Ouyang, Q.; Hu, X.; Cheng, Y.; Yan, M.; Teng, Y.; Pan, Y.; Yan, X.; Wang, Y.; Xie, W.; Zeng, X.; Jiang, S.; Bayaxi, N.; Zhu, X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 8
- Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trialZhang, P.; Zhang, Q. Y.; Hu, X.; Li, W.; Tong, Z.; Sun, T.; Teng, Y.; Wu, X.; Ouyang, Q.; Yan, X.; Cheng, J.; Liu, Q.; Feng, J.; Wang, X.; Xu, G.; Wu, F.; Xia, B.; Xu, B.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 1
- PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC)Zhang, Jian; Meng, Yanchun; Wang, Biyun; Wu, Xinhong; Zheng, Hongmei; Cai, Li; Chen, Wenyan; Wang, Leiping; Cao, Jun; Tao, Zhonghua; Li, Ting; Ni Sujie; Yu, Zhengyan; Chen, XueSong; Peng, Qiang; Hu, Xin; Yao, Wenqing; Hu, XichunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2-advanced breast cancer: A phase Ib study.
13阅读
